Mabwell Bioscience Announces Two Major Licensing Deals for 9MW3811 and 8MW0511

Mabwell andCalico Life Sciences LLCAn exclusive license agreement has been reached for IL-11 targeted therapies, including the Phase I clinical stage monoclonal antibody innovative drug 9MW3811.

According to the license agreement, Mabwell exclusively licensed Calico to have the exclusive rights to develop, manufacture, and commercialize 9MW3811 in all regions outside Greater China.

Calico will pay Mabwell a one-time, non-refundable upfront payment.$25 millionMoreover, Mabwell can additionally obtain a maximum total of$5.71 billionProximal, development, registration, and commercialization milestone payments, as well as tiered royalties based on net sales of the licensed product.

Mabwell has explored the therapeutic potential of 9MW3811 in age-related disease areas during preclinical studies, completed Phase I clinical studies in China and Australia, and been approved to conduct Phase I clinical studies in the United States.

Mabwell and its wholly-owned subsidiary Taikang Bio enter into the "New Drug Project Technology License Agreement" with Qilu Pharmaceutical for the marketed product Argatroban Injection a (trade name: Mailisheng, product code: 8 MW0511).

According to the license agreement, Mabwell has been granted an exclusive license.Qilu PharmaceuticalIn Greater China(Including mainland China, Hong Kong, Macao and Taiwan)The rights to develop, produce, improve, utilize, and commercialize licensed products in China.

In return, Taikang Bio can receive a total of up toRMB 500 millionThe upfront payment and sales milestone payments, as well as royalties of up to double-digit percentages of net sales of the licensed products. Among these, Qilu Pharmaceutical will pay a one-time, non-refundable upfront payment to Taikang Bio.RMB 380 million。